Neonatal Nav1.5 Protein Expression in Human Colorectal Cancer: Immunohistochemical Characterization and Clinical Evaluation
Authors:
- Elena LastraioliELElena Lastraioli
- Scott P. FraserSFScott P. Fraser
- R. Mine GuzelRGR. Mine Guzel
- Jessica IorioJIJessica Iorio
- Lapo BenciniLBLapo Bencini
- Emanuela ScarpiESEmanuela Scarpi
- Luca MesseriniLMLuca Messerini
- Vincenzo VillanacciVVVincenzo Villanacci
- Giulia CerinoGCGiulia Cerino
- Niccolo’ GhezziNGNiccolo’ Ghezzi
- Giuseppe PerroneGiuseppe Perrone
- Mustafa B. A. DjamgozMustafa B. A. Djamgoz
Open Access
Abstract
Voltage-gated Na+ channels (VGSCs) are expressed widely in human carcinomas and play a significant role in promoting cellular invasiveness and metastasis. However, human tissue-based studies and clinical characterization are lacking. In several carcinomas, including colorectal cancer (CRCa), the predominant VGSC is the neonatal splice variant of Nav1.5 (nNav1.5). The present study was designed to determine the expression patterns and clinical relevance of nNav1.5 protein in human CRCa tissues from patients with available clinicopathological history. The immunohistochemistry was made possible by the use of a polyclonal antibody (NESOpAb) specific for nNav1.5. The analysis showed that, compared with normal mucosa, nNav1.5 expression occurred in CRCa samples (i) at levels that were significantly higher and (ii) with a pattern that was more delineated (i.e., apical/basal or mixed). A surprisingly high level of nNav1.5 protein expression also occurred in adenomas, but this was mainly intracellular and diffuse. nNav1.5 showed a statistically significant association with TNM stage, highest expression being associated with TNM IV and metastatic status. Interestingly, nNav1.5 expression co-occurred with other biomarkers associated with metastasis, including hERG1, KCa3.1, VEGF-A, Glut1, and EGFR. Finally, univariate analysis showed that nNav1.5 expression had an impact on progression-free survival. We conclude (i) that nNav1.5 could represent a novel clinical biomarker (‘companion diagnostic’) useful to better stratify CRCa patients and (ii) that since nNav1.5 expression is functional, it could form the basis of anti-metastatic therapies including in combination with standard treatments.Keywords
This publication has 47 references indexed in Scilit:
- Therapeutic potential for phenytoin: targeting Nav1.5 sodium channels to reduce migration and invasion in metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Angiogenic Functions of Voltage-gated Na+ Channels in Human Endothelial CellsJournal of Biological Chemistry, 2011
- NaV1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H+ efflux in caveolaeOncogene, 2010
- Voltage-Gated Na+ Channel SCN5A Is a Key Regulator of a Gene Transcriptional Network That Controls Colon Cancer InvasionCancer Research, 2010
- Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progressionBMC Cancer, 2008
- Carbonic anhydrase IX in oligodendroglial brain tumorsBMC Cancer, 2008
- Epidermal growth factor upregulates motility of Mat‐LyLu rat prostate cancer cells partially via voltage‐gated Na+ channel activityJournal of Cellular Physiology, 2007
- A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivoProstate Cancer and Prostatic Diseases, 2005
- Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer MetastasisClinical Cancer Research, 2005
- The colorectal adenoma–carcinoma sequenceBritish Journal of Surgery, 2002